The Role of Nebulized Budesonide in the Treatment of Acute Exacerbations of COPD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00274222
Recruitment Status : Terminated
First Posted : January 10, 2006
Last Update Posted : January 10, 2006
Information provided by:
Inonu University

Brief Summary:
This study was designed to evaluate the hypothesis that nebulized budesonide) might be an alternative to systemic corticosteroids (SC) in the treatment of patients with acute exacerbations of COPD (AECOPD).

Condition or disease
COPD Acute Exacerbation

Detailed Description:
Patients, hospitalized with AECOPD, were randomized into three groups. Group I received only bronchodilator treatment (BDT), Group II received SC (40 mg prednisolon) plus BDT, and Group III received nebulized budesonide (NB)(1500 mcg qid) plus BDT. Improvement rates in multiple parameters during 10-day hospitalization, and acute exacerbation and re-hospitalization rates within one-month after discharge were compared between the groups.

Study Type : Observational
Enrollment : 120 participants
Study Start Date : January 2003
Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Budesonide

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • COPD patients who were admitted to our pulmonary department for an acute exacerbation were prospectively enrolled in the study

Exclusion Criteria:

  • COPD patients hospitalized with specific reasons like pneumonia, pulmonary emboli, congestive heart failure, pneumothorax etc. as the cause of acute exacerbation, or patients with risk of imminent respiratory failure requiring mechanical ventilation or direct admission to the ICU were excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00274222

Sponsors and Collaborators
Inonu University
Study Chair: HAKAN GUNEN, MD INONU UNIVERSITY PULMONARY MEDICINE Identifier: NCT00274222     History of Changes
Other Study ID Numbers: 2006-3
First Posted: January 10, 2006    Key Record Dates
Last Update Posted: January 10, 2006
Last Verified: January 2006

Keywords provided by Inonu University:
COPD, nebulized budesonide, systemic corticosteroids

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists